We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Once a drug is on the market, collecting safety data and assessing risks based on observational data are critical for evaluating and characterizing a product's risk profile and for making informed decisions to minimize those risks, the FDA said in a draft guidance released earlier this month.